Newly Diagnosed Multiple Myeloma Cohort
A collaboration with the Fred Hutch Cancer Center
Lead Collaborators:
Dr. Damian Green, Currently affiliated with Sylvester Comprehensive Cancer Center
Dr. Mary Kwok, Fred Hutch Cancer Center
Our study enrolled 25 transplant-eligible patients (ages 30 to 70) with newly diagnosed multiple myeloma (NDMM) requiring systemic therapy at the Fred Hutchinson Cancer Center.
The primary cohort consists of 17 patients treated with standard VRd (bortezomib, lenalidomide, dexamethasone) induction therapy, while an exploratory cohort of 8 patients received DVRd (daratumumab plus VRd). All sample collection from NDMM patients was carried out under the supervision of the Fred Hutch Cancer Center Institutional Review Board.
Therapy Considerations:
Patients were followed prospectively through standard-of-care induction therapy, which was administered for at least four cycles. By institutional standard, patients were required to achieve a “very good” partial response to proceed to transplant. This was achieved through the extension of induction therapy, regimen modification, or both. Induction was followed by high-dose melphalan (HDM) conditioning, autologous stem cell transplantation (ASCT), consolidation for two cycles, and lenalidomide maintenance therapy thereafter with dose adjustments made for medical indications.
Longitudinal Timepoints:
Blood and bone marrow samples were collected across the following specific therapeutic milestones:
Prior to induction therapy (Pre-Treatment; Abbreviated PreTx)
After two cycles of induction therapy (Post Induction Round 2; PI2C, blood only)
End of induction (End of Induction 1st Draw; EI)
60 days post-transplant (Post Transplant 60 Days; ASCT60d, blood only)
90 days post-transplant (Post Transplant 90 Days; ASCT90d, bone marrow biopsy obtained between 60 and 100 days post-transplant based on clinical discretion)
One year (MM Post Transplant 1 year; ASCT1y) and two years (MM Post Transplant 2 year; ASCT2y) post-transplant (based on sample availability)
Healthy Control Donors:
The study matched 32 healthy adult blood donors (ages 25-65) from the Sound Life Cohort, collected by the Benaroya Research Institute, and described in our Dynamics of Human Immune Health and Age project. Healthy donors were selected to control for baseline variables like sex, race, ethnicity, age, and CMV status. PBMCs from these donors were used as a healthy comparator to our NDMM cohort.
10 healthy bone marrow donors were obtained from commercial sources, prescreened for infectious diseases like HIV and hepatitis. BMMCs from these subjects were used as a healthy control dataset for our NDMM subjects.